We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Merck KGaA Expands and Extends their License of MetaCore from GeneGo

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Merck KGaA Expands and Extends their License of MetaCore from GeneGo "

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

GeneGo, Inc. has announced that Merck KGaA, Germany, has expanded their MetaCore license to allow all Merck KGaA employees to access MetaCore and the license is in perpetuity.

Merck KGaA values the completeness of content coverage in MetaCore from signaling ligands to core metabolic changes, its intuitive interface and the system's applicability in many therapeutic areas and biomarkers.

"We see MetaCore as a further step into systems biology, a novel discipline which holds much promise for pharmaceutical research," said Dr. Friedrich Rippmann, Director of Bio- and Chemoinformatics.

"We are very pleased to expand our relationship with Merck KGaA. Our experience with them as a customer is very positive, with excellent, constructive feedback and open exchange of development ideas," said Julie Bryant, Vice President of Business Development at GeneGo.

"Now, more groups at Merck KGaA will be able to use MetaCore in both early discovery and new compound safety testing."